Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-11-01
DOI
10.3389/fimmu.2017.01417
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice
- (2016) Xiangming Li et al. Expert Review of Vaccines
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
- (2016) Tadeusz Robak et al. SEMINARS IN ONCOLOGY
- Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation
- (2015) Gerhard Wingender et al. JOURNAL OF IMMUNOLOGY
- Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment
- (2015) Jennifer A Juno et al. Retrovirology
- The Regulatory Role of Invariant NKT Cells in Tumor Immunity
- (2015) Rosanna M. McEwen-Smith et al. Cancer Immunology Research
- The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8+ T Cell Generation
- (2015) Catherine Gottschalk et al. Frontiers in Immunology
- Biology of CD1- and MR1-Restricted T Cells
- (2014) Mariolina Salio et al. Annual Review of Immunology
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
- (2014) A. Heczey et al. BLOOD
- IL-10–producing NKT10 cells are a distinct regulatory invariant NKT cell subset
- (2014) Duygu Sag et al. JOURNAL OF CLINICAL INVESTIGATION
- Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
- (2014) W.-S. Chang et al. JOURNAL OF IMMUNOLOGY
- Targeted Delivery of α-Galactosylceramide to CD8α+Dendritic Cells Optimizes Type I NKT Cell–Based Antitumor Responses
- (2014) Elodie Macho-Fernandez et al. JOURNAL OF IMMUNOLOGY
- Mammalian Target of Rapamycin Complex 1 Orchestrates Invariant NKT Cell Differentiation and Effector Function
- (2014) Lianjun Zhang et al. JOURNAL OF IMMUNOLOGY
- Tuberous Sclerosis 1 Promotes Invariant NKT Cell Anergy and Inhibits Invariant NKT Cell-Mediated Antitumor Immunity
- (2014) J. Wu et al. JOURNAL OF IMMUNOLOGY
- NKT Cell Networks in the Regulation of Tumor Immunity
- (2014) Faith C. Robertson et al. Frontiers in Immunology
- iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
- (2014) Stéphanie Corgnac et al. Journal for ImmunoTherapy of Cancer
- Antibody–peptide–MHC fusion conjugates target non-cognate T cells to kill tumour cells
- (2013) Ben C. King et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
- (2013) Shin-ichiro Fujii et al. Frontiers in Immunology
- CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
- (2012) Stéphanie Corgnac et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up
- (2012) Famke L. Schneiders et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal TCR-redirected tumor cell killing
- (2012) Nathaniel Liddy et al. NATURE MEDICINE
- NKT TCR Recognition of CD1d- -C-Galactosylceramide
- (2011) O. Patel et al. JOURNAL OF IMMUNOLOGY
- A Rapid Fluorescence-Based Assay for Classification of iNKT Cell Activating Glycolipids
- (2011) Pooja Arora et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+ T Cells to Dendritic Cell-Based Vaccines
- (2011) Troels R. Petersen et al. PLoS One
- Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
- (2010) Kazuki Yamasaki et al. CLINICAL IMMUNOLOGY
- Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation
- (2010) T. Iyoda et al. INTERNATIONAL IMMUNOLOGY
- Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs
- (2010) Verena Semmling et al. NATURE IMMUNOLOGY
- Type I natural killer T cells suppress tumors caused by p53 loss in mice
- (2009) J. B. Swann et al. BLOOD
- Combination therapy ofin vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma
- (2009) Naoki Kunii et al. CANCER SCIENCE
- Kinetics and Cellular Site of Glycolipid Loading Control the Outcome of Natural Killer T Cell Activation
- (2009) Jin S. Im et al. IMMUNITY
- The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy
- (2009) M. Taniguchi et al. INTERNATIONAL IMMUNOLOGY
- PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
- (2009) V. V. Parekh et al. JOURNAL OF IMMUNOLOGY
- Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1
- (2009) S. Kojo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in mice
- (2008) Kathrin Stirnemann et al. JOURNAL OF CLINICAL INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now